Literature DB >> 11487279

The ability to accumulate deoxyuridine triphosphate and cellular response to thymidylate synthase (TS) inhibition.

S D Webley1, S J Welsh, A L Jackman, G W Aherne.   

Abstract

Thymidylate synthase (TS) is an important enzyme catalysing the reductive methylation of dUMP to dTMP that is further metabolized to dTTP for DNA synthesis. Loss of viability following TS inhibition occurs as a consequence of depleted dTTP pools and at least in some cell lines, accumulation of dUTP and subsequent misincorporation of uracil into DNA. The expansion in dUTP pools is largely determined by the expression of the pyrophosphatase, dUTPase. Our previous work has shown that following TS inhibition the ability to accumulate dUTP was associated with an earlier growth inhibitory effect. 3 human lung tumour cell lines and HT29 human colon tumour cells transfected with dUTPase have been used to investigate the relationship between loss of viability following TS inhibition and dUTP accumulation. Cell cycle arrest typical of TS inhibition was an early event in all cell lines and occurred irrespective of the ability to accumulate dUTP or p53 function. However, a large expansion of dUTP pools was associated with mature DNA damage (4 h) and an earlier loss of viability following TS inhibition compared to cells in which dUTP pools were not expanded. In A549 cells damage to mature DNA may have been exacerbated by significantly higher activity of the excision repair enzyme, uracil-DNA glycosylase. Consistent with results using different inhibitors of TS, transfection of dUTPase into HT29 cells significantly reduced the cytotoxicity of a 24 h but not 48 h exposure to ZD9331. Although loss of viability can be mediated through dTTP deprivation alone, the uracil misincorporation pathway resulted in an earlier commitment to cell death. The relevance of this latter pathway in the clinical response to TS inhibitors deserves further investigation. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11487279      PMCID: PMC2364072          DOI: 10.1054/bjoc.2001.1921

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  29 in total

1.  Time dependence of DNA lesions and growth inhibition by ICI D1694, a new quinazoline antifolate thymidylate synthase inhibitor.

Authors:  M B Yin; M A Guimaraes; Z G Zhang; M A Arredondo; Y M Rustum
Journal:  Cancer Res       Date:  1992-11-01       Impact factor: 12.701

Review 2.  Principles and practice of DNA filter elution.

Authors:  K W Kohn
Journal:  Pharmacol Ther       Date:  1991       Impact factor: 12.310

3.  Mechanism of thymineless death.

Authors:  M Goulian; B M Bleile; L M Dickey; R H Grafstrom; H A Ingraham; S A Neynaber; M S Peterson; B Y Tseng
Journal:  Adv Exp Med Biol       Date:  1986       Impact factor: 2.622

4.  Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole.

Authors:  N J Curtin; A L Harris; G W Aherne
Journal:  Cancer Res       Date:  1991-05-01       Impact factor: 12.701

5.  Purine modulation of methotrexate cytotoxicity in mammalian cell lines.

Authors:  I W Taylor; P Slowiaczek; P R Francis; M H Tattersall
Journal:  Cancer Res       Date:  1982-12       Impact factor: 12.701

6.  Biochemical effects of a quinazoline inhibitor of thymidylate synthetase, N-(4-(N-(( 2-amino-4-hydroxy-6-quinazolinyl)methyl)prop-2-ynylamino) benzoyl)-L-glutamic acid (CB3717), on human lymphoblastoid cells.

Authors:  R C Jackson; A L Jackman; A H Calvert
Journal:  Biochem Pharmacol       Date:  1983-12-15       Impact factor: 5.858

7.  Generalized blocking in S phase by methotrexate.

Authors:  J R Savage; R Prasad
Journal:  Mutat Res       Date:  1988-09       Impact factor: 2.433

8.  Uracil DNA-glycosylase. Purification and properties of this enzyme isolated from blast cells of acute myelocytic leukemia patients.

Authors:  S J Caradonna; Y C Cheng
Journal:  J Biol Chem       Date:  1980-03-25       Impact factor: 5.157

9.  Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase.

Authors:  A L Jackman; R Kimbell; G W Aherne; L Brunton; G Jansen; T C Stephens; M N Smith; J M Wardleworth; F T Boyle
Journal:  Clin Cancer Res       Date:  1997-06       Impact factor: 12.531

10.  Deoxyuridine triphosphatase (dUTPase) expression and sensitivity to the thymidylate synthase (TS) inhibitor ZD9331.

Authors:  S D Webley; A Hardcastle; R D Ladner; A L Jackman; G W Aherne
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

View more
  14 in total

Review 1.  TAS-102, a novel antitumor agent: a review of the mechanism of action.

Authors:  Heinz-Josef Lenz; Sebastian Stintzing; Fotios Loupakis
Journal:  Cancer Treat Rev       Date:  2015-06-06       Impact factor: 12.111

Review 2.  Uracil in DNA: consequences for carcinogenesis and chemotherapy.

Authors:  Sondra H Berger; Douglas L Pittman; Michael D Wyatt
Journal:  Biochem Pharmacol       Date:  2008-07-01       Impact factor: 5.858

Review 3.  Mechanisms of resistance to pemetrexed in non-small cell lung cancer.

Authors:  Jiaqi Liang; Tao Lu; Zhencong Chen; Cheng Zhan; Qun Wang
Journal:  Transl Lung Cancer Res       Date:  2019-12

4.  Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945.

Authors:  Radhakrishna G Pillai; Martin Forster; Meg Perumal; Fraser Mitchell; Julius Leyton; Franklin I Aibgirhio; Oksana Golovko; Ann L Jackman; Eric O Aboagye
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

5.  Uracil incorporation into genomic DNA does not predict toxicity caused by chemotherapeutic inhibition of thymidylate synthase.

Authors:  Yuhong Luo; Mike Walla; Michael D Wyatt
Journal:  DNA Repair (Amst)       Date:  2007-10-17

Review 6.  Participation of DNA repair in the response to 5-fluorouracil.

Authors:  M D Wyatt; D M Wilson
Journal:  Cell Mol Life Sci       Date:  2009-03       Impact factor: 9.261

Review 7.  Standing the test of time: targeting thymidylate biosynthesis in cancer therapy.

Authors:  Peter M Wilson; Peter V Danenberg; Patrick G Johnston; Heinz-Josef Lenz; Robert D Ladner
Journal:  Nat Rev Clin Oncol       Date:  2014-04-15       Impact factor: 66.675

8.  Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells.

Authors:  O H Temmink; E K Hoebe; K van der Born; S P Ackland; M Fukushima; G J Peters
Journal:  Br J Cancer       Date:  2007-01-29       Impact factor: 7.640

9.  Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage.

Authors:  Peter M Wilson; William Fazzone; Melissa J LaBonte; Heinz-Josef Lenz; Robert D Ladner
Journal:  Nucleic Acids Res       Date:  2008-11-16       Impact factor: 16.971

Review 10.  Apoptosis and molecular targeting therapy in cancer.

Authors:  Mohamed Hassan; Hidemichi Watari; Ali AbuAlmaaty; Yusuke Ohba; Noriaki Sakuragi
Journal:  Biomed Res Int       Date:  2014-06-12       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.